- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Duchenne Muscular Dystrophy Clinical Trial Pipeline Accelerates As 75+ Pharma Companies Rigorously Develop Drugs For Market Entry
DelveInsight's report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Duchenne Muscular Dystrophy pipeline landscape.
Jan. 28, 2026 at 7:07pm
Got story updates? Submit your updates here. ›
DelveInsight's 'Duchenne Muscular Dystrophy Pipeline Insight 2025' report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Duchenne Muscular Dystrophy pipeline landscape. It covers the Duchenne Muscular Dystrophy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Duchenne Muscular Dystrophy therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Why it matters
The Duchenne Muscular Dystrophy pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Duchenne Muscular Dystrophy treatment. This highlights the growing interest and efforts to address the unmet medical needs in this rare, progressive neuromuscular disorder.
The details
The report provides detailed insights about companies that are developing therapies for the treatment of Duchenne Muscular Dystrophy with aggregate therapies developed by each company. It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development. The report also covers Duchenne Muscular Dystrophy drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, different mechanism of action, and molecular type.
- On January 26, 2026- Cumberland Pharmaceuticals conducted a study with an optional open-label extension to determine the safety, pharmacokinetics (PK) and efficacy of two doses of oral ifetroban in subjects with DMD.
- On January 21, 2026- Italfarmaco conducted a study of GIVINOSTAT in all DMD (Duchenne's muscular dystrophy) patients who have been previously treated in one of the GIVINOSTAT studies.
- On January 09, 2026- Santhera Pharmaceuticals initiated a study have completed previous studies with vamorolone and continued to receive vamorolone under special programs.
- On January 05, 2026- Hoffmann-La Roche conducted a study to assess the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of satralizumab in participants with DMD.
- On January 05, 2026- Satellos Bioscience Inc. announced a global phase 2a trial of SAT-3247 in ambulatory DMD patients aged ≥ 7 and < 10 years.
The players
Santhera Pharmaceuticals
A Swiss pharmaceutical company focused on the development of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need.
Sarepta Therapeutics
An American commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases.
Italfarmaco
An Italian pharmaceutical company that develops and markets innovative drugs for the treatment of rare and severe diseases.
Wave Life Sciences Ltd
A clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases.
FibroGen
A biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, including pamrevlumab, an anti-CTGF antibody, for the treatment of fibrotic and proliferative disorders.
What they’re saying
“We must not let individuals continue to damage private property in San Francisco.”
— Robert Jenkins, San Francisco resident (San Francisco Chronicle)
“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”
— Gordon Edgar, grocery employee (Instagram)
The takeaway
The Duchenne Muscular Dystrophy pipeline report highlights the growing interest and efforts to address the unmet medical needs in this rare, progressive neuromuscular disorder, with 75+ active players working to develop 75+ pipeline therapies. This robust pipeline reflects the potential for new and innovative treatment options to emerge in the near future.
